The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Stocks•30 June 2026•

1 min read

Innovent Biologics gains exclusive rights to market Eli Lilly's Verzenios in China

Key Facts

1China's Innovent Biologics has entered into an agreement granting it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China.

The deal reflects a growing trend among Chinese pharma companies to strengthen their oncology presence through strategic partnerships. Innovent Biologics announced it has obtained exclusive commercialization rights for Eli Lilly's Verzenios (abemaciclib) in mainland China, per Reuters.

Innovent will leverage its extensive commercial network to distribute the already-approved drug for HR+/HER2- breast cancer. According to market data, Innovent's stock (1801.HK) closed at HKD 80.05 on June 29, 2026, while Eli Lilly (LLY) closed at USD 1,229.93. The agreement adds a new revenue stream without drug development risks.

Investors are focused on Innovent's ability to generate revenue from the drug in a competitive market. Trading data shows Innovent's range between HKD 75.2 and 82.4, offering near-term support and resistance around the current close. Upcoming financial results will be key to assessing the deal's impact.